FLOTEK INDUSTRIES INC/CN/ — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that FLOTEK INDUSTRIES INC/CN/ filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $136.09M | Mar 23, 2023 |
| FY2022 | Dec 31, 2021 | $43.27M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $53.14M | Mar 31, 2022 |
| FY2015 | Dec 31, 2015 | $77.01M | Jan 27, 2016 |
| FY2015 | Sep 30, 2015 | $87.94M | Jan 27, 2016 |
| FY2015 | Jun 30, 2015 | $87.03M | Jan 27, 2016 |
| FY2015 | Mar 31, 2015 | $82.37M | Jan 27, 2016 |
| FY2015 | Dec 31, 2014 | $124.50M | Jan 27, 2016 |
| FY2015 | Sep 30, 2014 | $116.76M | Jan 27, 2016 |
| FY2015 | Jun 30, 2014 | $105.32M | Jan 27, 2016 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $237.26M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $187.03M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $188.06M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $136.09M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $39.63M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $53.14M | Mar 31, 2022 |
| FY2019 | Dec 31, 2019 | $19.53M | Jun 11, 2020 |
| FY2019 | Sep 30, 2019 | $21.88M | Jun 11, 2020 |
| FY2019 | Jun 30, 2019 | $34.69M | Jun 11, 2020 |
| FY2019 | Mar 31, 2019 | $43.26M | Jun 11, 2020 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $72.51M | Mar 8, 2018 |
| FY2017 | Sep 30, 2017 | $79.46M | Mar 8, 2018 |
| FY2017 | Jun 30, 2017 | $85.18M | Mar 8, 2018 |
| FY2017 | Mar 31, 2017 | $79.95M | Mar 8, 2018 |
| FY2017 | Dec 31, 2016 | $70.60M | Mar 8, 2018 |
| FY2017 | Sep 30, 2016 | $64.34M | Mar 8, 2018 |
| FY2017 | Jun 30, 2016 | $64.08M | Mar 8, 2018 |
| FY2017 | Mar 31, 2016 | $63.81M | Mar 8, 2018 |
| FY2016 | Dec 31, 2015 | $63.86M | Feb 8, 2017 |
| FY2016 | Sep 30, 2015 | $74.05M | Feb 8, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $59.83M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $39.39M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $24.26M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | ($6.70M) | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $3.26M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($28.67M) | Mar 31, 2022 |
| FY2016 | Dec 31, 2016 | $22.81M | Feb 8, 2017 |
| FY2016 | Sep 30, 2016 | $22.35M | Feb 8, 2017 |
| FY2016 | Jun 30, 2016 | $21.72M | Feb 8, 2017 |
| FY2016 | Mar 31, 2016 | $23.79M | Feb 8, 2017 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $30.53M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $10.50M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $24.71M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | ($42.31M) | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | ($30.53M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($136.45M) | Mar 31, 2022 |
| FY2019 | Dec 31, 2019 | ($39.56M) | Jun 11, 2020 |
| FY2019 | Sep 30, 2019 | ($11.11M) | Jun 11, 2020 |
| FY2019 | Jun 30, 2019 | ($14.60M) | Jun 11, 2020 |
| FY2019 | Mar 31, 2019 | $32.99M | Jun 11, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $23.24M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $12.20M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $23.22M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | ($35.42M) | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | ($31.46M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($143.65M) | Mar 31, 2022 |
| FY2019 | Dec 31, 2019 | ($36.65M) | Jun 11, 2020 |
| FY2019 | Sep 30, 2019 | ($11.85M) | Jun 11, 2020 |
| FY2019 | Jun 30, 2019 | ($13.86M) | Jun 11, 2020 |
| FY2019 | Mar 31, 2019 | ($14.27M) | Jun 11, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.82M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $1.71M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $2.49M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $4.44M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $5.54M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $7.21M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $8.86M | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | $10.36M | Jun 11, 2020 |
| FY2019 | Dec 31, 2017 | $13.13M | Jun 11, 2020 |
| FY2018 | Dec 31, 2016 | $9.32M | Mar 8, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $28.05M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $24.71M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $27.83M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $27.12M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $20.17M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $22.76M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $27.98M | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | $31.47M | Jun 11, 2020 |
| FY2019 | Dec 31, 2017 | $41.49M | Jun 11, 2020 |
| FY2018 | Dec 31, 2016 | $43.75M | Mar 8, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.20M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $3.36M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($11.30M) | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | ($44.63M) | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | ($25.84M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($47.84M) | Mar 31, 2022 |
| FY2016 | Dec 31, 2016 | $2.05M | Feb 8, 2017 |
| FY2016 | Dec 31, 2015 | $25.47M | Feb 8, 2017 |
| FY2016 | Dec 31, 2014 | $42.64M | Feb 8, 2017 |
| FY2015 | Dec 31, 2013 | $39.24M | Jan 27, 2016 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $421.0K | Mar 23, 2023 |
| FY2022 | Dec 31, 2021 | $39.0K | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $1.43M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $2.41M | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | $3.56M | Jun 11, 2020 |
| FY2019 | Dec 31, 2017 | $4.20M | Jun 11, 2020 |
| FY2018 | Dec 31, 2016 | $13.07M | Mar 8, 2019 |
| FY2017 | Dec 31, 2015 | $16.39M | Mar 8, 2018 |
| FY2016 | Dec 31, 2014 | $9.34M | Feb 8, 2017 |
| FY2015 | Dec 31, 2013 | $15.01M | Jan 27, 2016 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $220.05M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $170.80M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $157.51M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $164.81M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $50.24M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $86.21M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $230.60M | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | $285.88M | Jun 11, 2020 |
| FY2018 | Dec 31, 2017 | $329.89M | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | $383.22M | Mar 8, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $106.99M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $56.90M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $55.55M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $162.21M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $30.05M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $39.04M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $58.57M | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | $84.26M | Jun 11, 2020 |
| FY2017 | Dec 31, 2017 | $64.63M | Mar 8, 2018 |
| FY2017 | Dec 31, 2016 | $95.51M | Mar 8, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $113.06M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $113.90M | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | $101.96M | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | $2.60M | Mar 12, 2025 |
| FY2023 | Dec 31, 2021 | $20.19M | Mar 15, 2024 |
| FY2022 | Dec 31, 2020 | $47.17M | Mar 23, 2023 |
| FY2021 | Dec 31, 2019 | $172.03M | Mar 31, 2022 |
| FY2020 | Dec 31, 2018 | $202.01M | Mar 16, 2021 |
| FY2018 | Dec 31, 2017 | $264.90M | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | $287.34M | Mar 8, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $0 | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | $8.09M | Mar 31, 2022 |
| FY2021 | Dec 31, 2019 | $0 | Mar 31, 2022 |
| FY2018 | Dec 31, 2018 | $0 | Mar 8, 2019 |
| FY2018 | Dec 31, 2017 | $37.18M | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | $56.66M | Mar 8, 2018 |
| FY2017 | Dec 31, 2015 | $55.80M | Mar 8, 2018 |
| FY2016 | Dec 31, 2014 | $55.80M | Feb 8, 2017 |
| FY2015 | Dec 31, 2013 | $66.27M | Jan 27, 2016 |
| FY2014 | Dec 31, 2012 | $26.94M | Jan 27, 2015 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($285.78M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($316.31M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($326.81M) | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | ($351.52M) | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | ($309.21M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($278.69M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($142.24M) | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | ($107.57M) | Jun 11, 2020 |
| FY2018 | Dec 31, 2017 | ($37.23M) | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | ($9.83M) | Mar 8, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.73M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $4.40M | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | $5.85M | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | $12.29M | Mar 12, 2025 |
| FY2023 | Dec 31, 2021 | $11.53M | Mar 15, 2024 |
| FY2022 | Dec 31, 2020 | $38.66M | Mar 23, 2023 |
| FY2021 | Dec 31, 2019 | $100.58M | Mar 31, 2022 |
| FY2020 | Dec 31, 2018 | $3.04M | Mar 16, 2021 |
| FY2018 | Dec 31, 2017 | $4.58M | Mar 8, 2019 |
| FY2018 | Dec 31, 2016 | $4.82M | Mar 8, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $40.00M | Mar 16, 2026 |
| FY2023 | Dec 31, 2023 | $239.0K | Mar 15, 2024 |
| FY2017 | Dec 31, 2017 | $27.95M | Mar 8, 2018 |
| FY2017 | Dec 31, 2016 | $48.40M | Mar 8, 2018 |
| FY2016 | Dec 31, 2015 | $50.55M | Feb 8, 2017 |
| FY2015 | Dec 31, 2014 | $44.04M | Jan 27, 2016 |
| FY2014 | Dec 31, 2013 | $62.11M | Jan 27, 2015 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | 1 | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | (3) | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | (2) | Mar 31, 2022 |
| FY2019 | Dec 31, 2019 | 0 | Jun 11, 2020 |
| FY2019 | Sep 30, 2019 | 0 | Jun 11, 2020 |
| FY2019 | Jun 30, 2019 | 0 | Jun 11, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Jun 11, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | (3) | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | (2) | Mar 31, 2022 |
| FY2019 | Dec 31, 2019 | 0 | Jun 11, 2020 |
| FY2019 | Sep 30, 2019 | 0 | Jun 11, 2020 |
| FY2019 | Jun 30, 2019 | 0 | Jun 11, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Jun 11, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 30.13M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | 29.83M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | 29.66M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | 12.96M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | 73.46M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | 73.09M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 59.51M | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | 57.34M | Jun 11, 2020 |
| FY2018 | Dec 31, 2017 | 56.76M | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | 56.97M | Mar 8, 2018 |